Doxazosin: Effective Blood Pressure and BPH Management
| Product dosage: 1 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.38 | $46.18 (0%) | 🛒 Add to cart |
| 180 | $0.35 | $69.27 $62.24 (10%) | 🛒 Add to cart |
| 270 | $0.32 | $103.90 $86.33 (17%) | 🛒 Add to cart |
| 360 | $0.31
Best per pill | $138.53 $110.43 (20%) | 🛒 Add to cart |
| Product dosage: 2 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.19 (0%) | 🛒 Add to cart |
| 90 | $0.69 | $73.78 $62.24 (16%) | 🛒 Add to cart |
| 120 | $0.63 | $98.38 $75.29 (23%) | 🛒 Add to cart |
| 180 | $0.57 | $147.57 $102.40 (31%) | 🛒 Add to cart |
| 270 | $0.52 | $221.35 $141.55 (36%) | 🛒 Add to cart |
| 360 | $0.50
Best per pill | $295.14 $181.70 (38%) | 🛒 Add to cart |
| Product dosage: 4 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.41 | $42.16 (0%) | 🛒 Add to cart |
| 60 | $1.14 | $84.33 $68.26 (19%) | 🛒 Add to cart |
| 90 | $1.06 | $126.49 $95.37 (25%) | 🛒 Add to cart |
| 120 | $1.01 | $168.65 $121.47 (28%) | 🛒 Add to cart |
| 180 | $0.97 | $252.98 $174.67 (31%) | 🛒 Add to cart |
| 270 | $0.94 | $379.47 $253.98 (33%) | 🛒 Add to cart |
| 360 | $0.93
Best per pill | $505.95 $333.29 (34%) | 🛒 Add to cart |
Synonyms | |||
Doxazosin is a selective alpha-1 adrenergic receptor antagonist belonging to the quinazoline class, prescribed primarily for the management of hypertension and the symptomatic treatment of benign prostatic hyperplasia (BPH). It functions by inducing peripheral vasodilation and relaxing smooth muscle in the prostate and bladder neck, leading to reduced vascular resistance and improved urinary flow. This medication is available in immediate and extended-release formulations, allowing for tailored therapeutic regimens based on individual patient profiles and clinical indications. Its dual-action efficacy makes it a valuable option in urological and cardiovascular pharmacotherapy.
Features
- Selective alpha-1 adrenergic blockade
- Available in immediate-release (Doxazosin) and extended-release (Doxazosin XL) tablets
- Dosage strengths: 1 mg, 2 mg, 4 mg, 8 mg (immediate-release); 4 mg, 8 mg (extended-release)
- Administered orally, typically once daily
- Metabolized hepatically via CYP3A4 isoenzyme
- Excreted primarily in feces, with minor renal elimination
Benefits
- Lowers blood pressure effectively by reducing peripheral vascular resistance
- Improves urinary flow and reduces symptoms of BPH, such as hesitancy, nocturia, and incomplete emptying
- May improve lipid profiles by modestly reducing total cholesterol and LDL levels
- Does not adversely affect glucose metabolism, making it suitable for diabetic patients
- Single daily dosing supports adherence and convenience
- Can be used as monotherapy or in combination with other antihypertensives
Common use
Doxazosin is indicated for the treatment of mild to moderate hypertension, either as monotherapy or in combination with other antihypertensive agents such as diuretics or beta-blockers. It is also approved for the symptomatic management of benign prostatic hyperplasia, alleviating lower urinary tract symptoms including weak stream, urgency, and frequency. Off-label uses may include the treatment of ureteral stones due to its smooth muscle relaxant properties and adjunctive management in pheochromocytoma under specialized supervision.
Dosage and direction
For hypertension, the initial dose is 1 mg once daily, preferably at bedtime to minimize the risk of first-dose syncope. The dose may be titrated upward at 1–2 week intervals based on blood pressure response, with a maximum recommended dose of 16 mg daily. For BPH, the starting dose is also 1 mg daily, with titration to 2 mg, 4 mg, and up to 8 mg as tolerated and needed for symptom control. The extended-release formulation (Doxazosin XL) should be taken with breakfast and must not be crushed or chewed. Dosage adjustments are necessary in hepatic impairment, and routine monitoring of blood pressure and BPH symptoms is advised during therapy.
Precautions
Orthostatic hypotension, with or without syncope, may occur, particularly with the initial dose or after dosage increases. Patients should be advised to avoid driving or operating machinery for 24 hours after the first dose or any dose escalation. Caution is warranted in patients with severe hepatic impairment, as doxazosin is extensively metabolized in the liver. Regular ophthalmic exams are recommended due to a potential association with intraoperative floppy iris syndrome during cataract surgery. Use with caution in patients with gastrointestinal narrowing or obstruction if using the extended-release formulation.
Contraindications
Doxazosin is contraindicated in patients with known hypersensitivity to doxazosin, other quinazolines, or any component of the formulation. It is also contraindicated in patients with a history of orthostatic hypotension and should not be used concurrently with other alpha-adrenergic blocking agents due to the additive hypotensive effects. The extended-release formulation is contraindicated in patients with preexisting severe gastrointestinal narrowing.
Possible side effect
Common adverse reactions include dizziness (15–19%), fatigue (8–12%), headache (5–9%), and somnolence (5–6%). Orthostatic hypotension occurs in approximately 0.3–1% of patients. Less frequently reported effects include edema, palpitations, nausea, rhinitis, and blurred vision. Rare but serious side effects may include priapism, which requires immediate medical attention, and severe hypotension. Most side effects are dose-dependent and may diminish with continued therapy.
Drug interaction
Concomitant use with other antihypertensive agents, phosphodiesterase-5 inhibitors (e.g., sildenafil), or nitrates may potentiate hypotensive effects. Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir may increase doxazosin plasma concentrations. Conversely, inducers of CYP3A4 like rifampin may reduce its efficacy. Nonsteroidal anti-inflammatory drugs may attenuate the antihypertensive effect. Additive effects may occur with other alpha-blockers or medications that cause hypotension.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose is not recommended due to the increased risk of hypotension.
Overdose
Manifestations of overdose include severe hypotension, circulatory collapse, and shock. Management involves placing the patient in a supine position and initiating supportive measures, such as intravenous fluids and vasopressors if necessary. Gastric lavage or activated charcoal may be considered if ingestion was recent. Hemodialysis is not effective due to high protein binding.
Storage
Store at room temperature (20–25°C or 68–77°F), in a tightly closed container, protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or discontinuing any medication. Individual responses to doxazosin may vary, and therapeutic decisions should be based on clinical evaluation and patient-specific factors.
Reviews
Clinical studies and meta-analyses consistently demonstrate doxazosin’s efficacy in reducing blood pressure and improving urinary symptoms in BPH. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), doxazosin showed effectiveness in blood pressure control but was associated with a higher incidence of heart failure compared to diuretics, limiting its use as first-line monotherapy in hypertension. For BPH, it is regarded as a well-tolerated option with rapid onset of symptom relief. Patient satisfaction often relates to improved quality of life due to better urinary control and minimal metabolic interference.